Table 2. Benzodiazepine Visit Rate by Indication.
| Indicationa | No. of Benzodiazepine
Visits, 1 Million |
Unadjusted Estimated Benzodiazepine Visit Rate, % (95% CI) | ||||
|---|---|---|---|---|---|---|
| 2003 | 2015 | 2003 | 2015 | P Valueb | Adjusted OR (95% CI)c | |
| Anxiety and depression | 12.8 | 23.7 | 26.6 (22.6-31.0) | 33.5 (28.8-38.6) | .003 | 1.43 (1.05-1.95) |
| Back and chronic pain | 4.9 | 15.1 | 3.6 (2.6-4.9) | 8.5 (6.0-11.9) | <.001 | 2.65 (1.65-4.26) |
| Insomnia | 2.1 | 3.4 | 26.9 (19.3-36.0) | 25.6 (15.3-39.6) | .72 | 0.94 (0.46-1.92) |
| Neurologicd | 3.3 | 5.0 | 6.8 (4.8-9.5) | 8.7 (6.2-12.1) | <.001 | 1.37 (0.85-2.22) |
| Other | 9.1 | 24.5 | 1.8 (1.4-2.2) | 4.4 (3.7-5.2) | <.001 | 2.50 (1.90-3.29) |
Abbreviation: OR, odds ratio.
a
A visit can be ascribed to multiple diagnoses.
b
Calculated using χ2 trend test.
c
Adjusted for age, sex, race, insurance, region, and location.
d
Includes headache, seizures, vertigo, and movement disorders.